Dr Reddy’s Laboratories Ltd (DRL) has launched a drug for heart stroke Patients. Drug Somazina, the innovator brand of Citicoline in the Indian market. This product has been used for the treatment of post-stroke patients around the world. DRL brought the drug to India in partnership with Ferrer Internacional SA of Spain. This drug will help the patients to recover better, who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
Dr Reddy’s Laboratories Launches Drug ‘Somazina’ :
Somazina is used for the management of stroke and has been used for the treatment of post-stroke patients around the world. Senior Vice President and Head of India Business, Dr Reddy’s Laboratories said, We are excited about the partnership with Ferrer and launch of Somazina which addresses significant unmet need in patients, whose quality of life gets severely compromised after having a stroke.”
During the launch the company officials said, “This is an important product in the management of stroke and has been used for treatment of post-stroke patients around the world.” Dr Reddy’s Laboratories, on Friday with the global innovator of Citicoline, Ferrer International S A of Spain has made Somazina available in India. Somazina and recent acquisition of Nootropil through the UCB brands’ acquisition with the launch of these medicins in India, the company looks forward to building its presence in the neurology segment.
Dr Reddy’s Laboratories, on Friday, ended 0.52 per cent lower at Rs. 3,491.60 apiece on the BSE.